In Re Spero Therapeutics, Inc. Securities Litigation

Track this case

Case overview

Case Number:

1:22-cv-03125

Court:

New York Eastern

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

LaShann DeArcy Hall

Firms

Companies

Sectors & Industries:

  1. October 29, 2024

    Biopharma Co. Escapes Investor Suit Over Drug Approval Lies

    Biopharmaceutical company Spero Therapeutics Inc. has escaped a proposed investor class action accusing it of concealing warning signs that it would not secure regulatory approval of one of its drugs, with the court ruling that Spero's interactions with the U.S. Food and Drug Administration do not indicate Spero should have known its application would be rejected.

  2. May 27, 2022

    Biopharma Co.'s Lies Caused Investor Losses, Suit Claims

    Biopharmaceutical company Spero Therapeutics Inc. has been hit with a proposed class action suit from an investor who claims the company made false and misleading statements about the regulatory approval of one of its developed drugs, causing stock-price drops and financial damages to shareholders as a result.